| __timestamp | Galapagos NV | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 45967000 |
| Thursday, January 1, 2015 | 129714000 | 114737000 |
| Friday, January 1, 2016 | 139574000 | 183204000 |
| Sunday, January 1, 2017 | 218502000 | 231644000 |
| Monday, January 1, 2018 | 322876000 | 293998000 |
| Tuesday, January 1, 2019 | 427320000 | 357355000 |
| Wednesday, January 1, 2020 | 523667000 | 412084000 |
| Friday, January 1, 2021 | 491707000 | 497153000 |
| Saturday, January 1, 2022 | 515083000 | 705789000 |
| Sunday, January 1, 2023 | 241294000 | 648449000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Ultragenyx Pharmaceutical Inc. and Galapagos NV have demonstrated significant investments in R&D, reflecting their dedication to advancing medical breakthroughs. From 2014 to 2023, Ultragenyx's R&D expenses surged by over 1,300%, peaking in 2022 with a remarkable 705 million USD. Meanwhile, Galapagos NV's R&D spending grew by approximately 370%, reaching its zenith in 2020. Notably, Ultragenyx surpassed Galapagos in R&D expenditure from 2021 onwards, highlighting its aggressive push in the biotech arena. This financial commitment underscores the competitive landscape of the industry, where strategic investments in R&D can lead to groundbreaking therapies and substantial market advantages.
R&D Insights: How AstraZeneca PLC and Ultragenyx Pharmaceutical Inc. Allocate Funds
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Galapagos NV
Research and Development: Comparing Key Metrics for argenx SE and Ultragenyx Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
R&D Spending Showdown: Blueprint Medicines Corporation vs Ultragenyx Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV
Amneal Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Amneal Pharmaceuticals, Inc. vs Galapagos NV
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Vericel Corporation
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending